Brought to you by 
CardioKinetix brings in $44mm through its Series E venture round; closed at $48mm
28 Feb 2013
Executive Summary
CardioKinetix Inc. has raised $44mm through a two-tranche Series E venture round. New investors SV Life Sciences and New Leaf Venture Partners led (and will each contribute one board member) and were joined by current shareholders US Venture Partners, JP Morgan Partners, H&Q Healthcare Investors, and H&Q Life Sciences Investors. CardioKinetix has created the CE-Marked Parachute transcatheter implant for ventricular partitioning in myocardical infarction patients.
Deal Industry
- Medical Devices
-
Medical Devices
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CardioKinetix brings in $44mm through its Series E venture round; closed at $48mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice